MSCLF
Satellos Bioscience Inc.
Set alert
6.25 USD 0.00 0.00%
5.77 Day range 6.39
0.88 52-week range 12.50
- YTD
- +6.29%
- 1 year
- -5.16%
- Open
- 5.79
- Prev close
- 6.25
- Mkt cap
- 96.62M
- Vol
- 62.40K
- Avg vol
- 12.13K
- EPS
- 2.57
- P/E
- 2.43
More statistics
- Low
- 5.77
- High
- 6.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.05 | -0.06 | -0.01 | -20.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.05 | -0.04 | +0.01 | +20.00% |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.04 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -0.01 | -0.04 | -0.03 | -300.00% |
| Nov 22, 2023 | Sep 1, 2023 | -0.02 | -0.02 | 0.00 | 0.00% |
| Aug 28, 2023 | Jun 1, 2023 | -0.03 | -0.04 | -0.01 | -33.33% |
News
- Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
- Satellos to Participate in Upcoming Investor Conferences
- Satellos Granted Composition of Matter Patent for Forazapadin
- Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
- Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
- Satellos to Present at the 31st Annual Congress of the World Muscle Society
- Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
- Satellos to Participate in Upcoming Investor Conferences
- Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
- Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Your note
Sign in to keep a note on MSCLF — it syncs with the Stock Master app.